Table 3.
Statistics of individual biomarkers in healthy controls, benign conditions, and PDAC patients.
| Biomarker | Subgroup | Number | Min | Max | Median | Mean | IQR |
|---|---|---|---|---|---|---|---|
| CA-125 | Controls | 70 | 1.7 | 505.9 | 5.8 | 29.9 | 9.0 |
| CP | 58 | 2.1 | 201.4 | 9.8 | 23.0 | 18.2 | |
| IPMN | 52 a | 1.9 | 506.1 | 4.8 | 17.4 | 4.8 | |
| Early stage | 55 a | 2.2 | 244.7 | 8.9 | 29.6 | 19.8 | |
| Late stage | 79 a | 2.8 | 896.7 | 24.4 | 79.0 | 67.4 | |
| HE4 | Controls | 70 | 0.4 | 1.8 | 1.0 | 1.0 | 0.3 |
| CP | 58 | 0.7 | 3.9 | 1.5 | 1.7 | 0.8 | |
| IPMN | 52 a | 0.7 | 2.7 | 1.3 | 1.5 | 0.6 | |
| Early stage | 56 | 0.4 | 8.6 | 1.5 | 1.8 | 0.7 | |
| Late stage | 80 a | 0.4 | 21.2 | 1.7 | 2.1 | 0.7 | |
| KRT19 | Controls | 67 a | 0.7 | 115.5 | 2.4 | 7.6 | 2.8 |
| CP | 57 a | 0.7 | 119.1 | 1.9 | 6.6 | 3.2 | |
| IPMN | 51 a | 0.7 | 38.7 | 1.9 | 3.6 | 2.8 | |
| Early stage | 55 a | 0.7 | 866.5 | 2.7 | 24.0 | 5.5 | |
| Late stage | 76 a | 0.8 | 267.6 | 2.7 | 7.9 | 3.6 | |
| FOLR1 | Controls | 68 a | 0.7 | 174.4 | 1.5 | 7.6 | 1.3 |
| CP | 57 a | 0.8 | 20.0 | 1.4 | 2.7 | 0.9 | |
| IPMN | 52 a | 0.8 | 360.5 | 1.6 | 8.7 | 0.8 | |
| Early stage | 55 a | 0.7 | 158.5 | 1.6 | 5.5 | 1.1 | |
| Late stage | 79 a | 0.8 | 165.4 | 1.6 | 6.2 | 1.0 | |
| CEA | Controls | 70 | 0.4 | 55.0 | 1.3 | 4.9 | 2.0 |
| CP | 58 | 0.3 | 13.3 | 1.4 | 1.9 | 1.3 | |
| IPMN | 53 | 0.4 | 44.0 | 1.3 | 3.9 | 1.8 | |
| Early stage | 56 | 0.4 | 152.8 | 2.0 | 6.3 | 3.3 | |
| Late stage | 82 | 0.5 | 224.3 | 4.1 | 14.9 | 6.6 | |
| HGF | Controls | 70 | 1.2 | 57.5 | 2.2 | 6.3 | 3.8 |
| CP | 58 | 1.3 | 9.8 | 2.7 | 3.4 | 2.3 | |
| IPMN | 53 | 1.5 | 43.0 | 2.4 | 5.2 | 1.2 | |
| Early stage | 55 a | 1.5 | 43.8 | 2.9 | 4.9 | 2.5 | |
| Late stage | 80 a | 1.6 | 38.8 | 2.7 | 4.8 | 2.0 | |
| OPG | Controls | 70 | 0.3 | 367.8 | 2.0 | 25.2 | 14.1 |
| CP | 58 | 0.1 | 90.7 | 1.3 | 4.9 | 4.1 | |
| IPMN | 53 | 0.4 | 552.8 | 1.2 | 38.2 | 4.1 | |
| Early stage | 54 a | 0.4 | 150.6 | 1.5 | 10.9 | 2.3 | |
| Late stage | 79 a | 0.2 | 300.4 | 1.3 | 12.7 | 1.6 | |
| Tie-2 | Controls | 70 | 14.2 | 182.1 | 51.6 | 58.1 | 20.3 |
| CP | 58 | 27.3 | 131.9 | 59.9 | 65.0 | 26.5 | |
| IPMN | 53 | 33.0 | 183.8 | 51.5 | 57.4 | 18.8 | |
| Early stage | 55 a | 23.5 | 255.9 | 56.2 | 61.0 | 23.5 | |
| Late stage | 79 a | 26.2 | 162.0 | 63.5 | 65.9 | 25.9 | |
| CA19-9 | Controls | 70 | <0.1 | 71.6 | 11.4 | 15.0 | 13.3 |
| CP | 58 | <0.1 | 203.2 | 20.3 | 31.3 | 33.1 | |
| IPMN | 53 | <0.1 | 386.9 | 16.7 | 28.8 | 18.5 | |
| Early stage | 56 | <0.1 | 27027.8 | 130.8 | 1169.7 | 725.1 | |
| Late stage | 82 | <0.1 | 25110.7 | 354.8 | 1693.2 | 1569.7 |
NOTE: all biomarkers are at ng/mL, except CA19-9 at U/mL. IQR, interquartile range. a Missing data in 16 cases due to either insufficient sample (2 cases) or result outside the assay measuring range (14 cases). CP, chronic pancreatitis. IPMN, intraductal papillary mucinous neoplasm.